June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Reduction of Macular Edema and Pro-permeability Factors after Dexamethasone Implant Injection in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study
Author Affiliations & Notes
  • Tahreem Aman Mir
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Gulnar Hafiz
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Adrienne Scott
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Raafay Sophie
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Syed Mahmood Shah
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Howard S Ying
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Lu Lili
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Connie J Chen
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • J Peter Campbell
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Peter Campochiaro
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD
  • Footnotes
    Commercial Relationships Tahreem Mir, None; Gulnar Hafiz, None; Adrienne Scott, None; Raafay Sophie, None; Syed Mahmood Shah, None; Howard Ying, Lutronics (C), Regeneron (F); Lu Lili, None; Connie Chen, None; J Campbell, None; Peter Campochiaro, Allergan, Inc (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1282. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tahreem Aman Mir, Gulnar Hafiz, Adrienne Scott, Raafay Sophie, Syed Mahmood Shah, Howard S Ying, Lu Lili, Connie J Chen, J Peter Campbell, Peter Campochiaro; Reduction of Macular Edema and Pro-permeability Factors after Dexamethasone Implant Injection in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1282.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To measure changes in aqueous levels of vasoactive proteins in patients with macular edema due to retinal vein occlusion (RVO) after injection of a dexamethasone implant and correlate them with changes in edema.

Methods: Twenty-three subjects with central RVO (CRVO) and 17 with branch RVO (BRVO) who had persistent/recurrent edema despite prior injections of a vascular endothelial growth factor (VEGF)-neutralizing protein had an aqueous tap at baseline, 4 weeks and 16 weeks after intraocular injection of a dexamethasone implant. At each study visit, patients had best-corrected visual acuity (BCVA) measured by Early Treatment Diabetic Retinopathy Study protocol and measurement of center subfield thickness (CST) by spectral domain optical coherence tomography. Aqueous levels of vasoactive proteins were measured by protein array or enzyme-linked immunosorbent assay (ELISA). The main outcome was correlation of changes between baseline and week 4 in aqueous levels of vasoactive proteins with changes in edema.

Results: Thirty-two of a possible 55 vasoactive proteins were detected in the aqueous at baseline. Four weeks after injection of a dexamethasone implant, hepatocyte growth factor (HGF), endocrine gland-vascular endothelial growth factor (EG-VEGF), insulin-like growth factor binding proteins (IGFBPs) 1, 2, and 3, activin-A and endostatin were reduced by ≥30% in at least 4 of 11 eyes with BRVO and at least 4 of 11 eyes with CRVO. In 18 RVO eyes (12 CRVO, 6 BRVO) baseline levels of HGF and VEGF measured by ELISA were 168.2 ± 20.1 pg/ml and 78.7 ± 10.0 pg/ml; in association with reduced edema at week 4, HGF was reduced in 12 of 18 eyes and VEGF was reduced in 10 of 17. There was a correlation between reduction in persephin (PCC=0.638, p=0.003) and pentraxin 3 (PCC=0.682, p=0.014) with reduction in excess foveal thickening.

Conclusions: Dexamethasone implants reduce levels of several proteins that may have pro-permeability activity, potentially an appealing multitargeted approach for patients with macular edema. It would be valuable to identify proteins that contribute to chronic edema to gain insight into molecular mechanisms. This study has identified candidates that deserve further study including HGF, EG-VEGF and activin-A. The potential effects of changes in IGFBPs and persephin also deserve investigation.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×